| 000 | 01759 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513031702.0 | ||
| 264 | 0 | _c19950614 | |
| 008 | 199506s 0 0 eng d | ||
| 022 | _a0277-3732 | ||
| 024 | 7 |
_a10.1097/00000421-199506000-00011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDi Leo, A | |
| 245 | 0 | 0 |
_aEpirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cJun 1995 |
||
| 300 |
_a239-44 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAmbulatory Care |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aHeart Failure _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMedroxyprogesterone Acetate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms, Hormone-Dependent _xdrug therapy |
| 650 | 0 | 4 |
_aPain _xdrug therapy |
| 650 | 0 | 4 | _aPain Measurement |
| 650 | 0 | 4 | _aPalliative Care |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aBajetta, E | |
| 700 | 1 | _aBuzzoni, R | |
| 700 | 1 | _aBochicchio, A M | |
| 700 | 1 | _aNolè, F | |
| 700 | 1 | _aBiganzoli, L | |
| 700 | 1 | _aD'Aprile, M | |
| 700 | 1 | _aVeltri, E | |
| 700 | 1 | _aComella, G | |
| 700 | 1 | _aAitini, E | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 18 _gno. 3 _gp. 239-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00000421-199506000-00011 _zAvailable from publisher's website |
| 999 |
_c7537719 _d7537719 |
||